Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | P-BCMA-101 CAR-T cells + Rimiducid |
Synonyms | |
Therapy Description |
P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
P-BCMA-101 CAR-T cells | P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). | |||
Rimiducid | AP1903|AP-1903|AP 1903 | Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|